Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 7, 2012

View Archived Issues

Strategies to overcome drug resistance in mutation-dependent cancers

Varenicline as a potential treatment for methamphetamine dependence

New antibodies presented for P. falciparum infection

Merck & Co. patents novel SYK inhibitors for respiratory disorders

Development of a novel, simple to use, non-radiological neuropathy-detection technology

Joint grant awarded for prostate cancer drug research

Scientists at Rhizen Pharmaceuticals present new PI3K inhibitors

Photocure discloses initial results from phase IIb trial of Cevira

Synta Pharmaceuticals discloses new inhibitors of CRAC and cytokine production

Type I interferon receptor 1 MAb evaluated in patients with scleroderma

Omeros patents new anti-MASP-2 monoclonal antibodies

Constellation Pharmaceuticals presents novel BRD4 inhibitors

First-in-patient trial data updated for PF-03084014

Japanese group divulges new agents for Helicobacter pylori infections

Preliminary phase I data presented on MLN-0128 for advanced solid malignancies

Cerecor signs option with Johns Hopkins for DAAO inhibitor platform

IMI launches new drug development projects

Peregrine Pharmaceuticals advances Cotara into pivotal phase III trial

RXi Pharmaceuticals begins second phase I study of anti-scarring drug

Thomson Reuters announces newest intelligence solution for drug development

Vical licenses adjuvant to Cyvax for malaria vaccines

FDA approves La Jolla Pharmaceutical's IND for CKD drug

Japan Tobacco applies for approval of single-tablet anti-HIV regimen in Japan

CLAVELA study completes enrollment

Gentium to begin phase I development of defibrotide in Japan

Regulatory approvals received for new study of Vacc-4x

Protalix and Pfizer sign new agreement for clinical development of Elelyso

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...